Clinical trials: Dementia, Alzheimer's Type
Alzheimer's Disease, Early Onset, Logopenic Progressive Aphasia
Tau Imaging in Young Onset Dementia
The central goal of this study is to determine and compare the similarities and differences in regional brain uptake of [18F]T807 in patients with typical Alzheimer's Disease (AD), Posterior Cortical Atrophy (PCA), and Logopenic…
- Conditions
- Alzheimer's Disease, Early Onset, Logopenic Progressive Aphasia, Posterior Cortical Atrophy (PCA)
- Trial name
- NCT02289118
- Testing
- [18F]-T807 imaging tracer
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Pennsylvania
Alzheimer Disease, Early Onset
Digital Evaluations and Technologies Enabling Clinical Translation for AD
The DETECT-AD study (stands for "Digital Evaluations and Technologies Enabling Clinical Translation for Alzheimer's Disease") is a new study designed to improve clinical trials for early Alzheimer's disease.
- Trial name
- DETECT-AD (NCT05385913)
- Testing
- Multivitamin-no intervention
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Oregon Health and Science University
Alzheimer Disease, Caregivers of Alzheimer's Disease or Memory Problem Patients
Psychological Counseling Program for Alzheimer's Patients' Caregivers
Purpose: To investigate the effects of a psychological counseling program (PsychoCP) applied to caregivers of Alzheimer's patients on perceived stress, psychological well-being and care burden.
- Conditions
- Alzheimer Disease, Caregivers of Alzheimer's Disease or Memory Problem Patients, Perceived Stress, Well-Being (Psychological Flourishing)
- Trial name
- PsychoCP (NCT06755476)
- Testing
- Psychological Counseling Program
- Volunteers
- 80 people
- Sponsor
- Aydan Akkurt Yalçıntürk
Alzheimer Disease, Mild Cognitive Impairment
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants
Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD)
- Trial name
- NCT05469360
- Testing
- NIO752
- Where
- 10 sites in Finland, France and 2 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Early Alzheimer's Disease
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study…
- Trial name
- EVOKE (NCT04777396)
- Testing
- Semagludtide
- Where
- 447 sites in United States, Argentina and 35 more
- Volunteers
- 1,840 people
- Sponsor
- Novo Nordisk A/S
Alzheimer Disease
Transmagnetic Stimulation Pilot in Early Stage Alzheimer's Disease
Alzheimer's disease (AD) is a progressive neurodegenerative condition affecting 6.2 million individuals in the United States, resulting in an annual cost of care of $305 billion.
- Trial name
- NCT05292222
- Testing
- Intermittent theta burst stimulation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- HealthPartners Institute
Alzheimer Disease, Healthy Aging
Developing an Artificial Intelligence System to Detect Cognitive Impairment
Alzheimer's disease dementia (AD) is a debilitating and prevalent neurodegenerative disease in older adults globally. Cognitive impairment, a hallmark of AD, is assessed through verbal tests that require high specialization, and…
- Conditions
- Alzheimer Disease, Healthy Aging, Mild Cognitive Impairment
- Trial name
- NCT05794451
- Where
- Israel
- Volunteers
- 3,413 people, healthy volunteers welcome
- Sponsor
- University of Haifa
Mild Cognitive Impairment (MCI), Alzheimer Disease (AD)
Remote Digital Assessments for Cognitive Disorders
Memory and thinking problems in older adults, including mild cognitive impairment (MCI) and Alzheimer's disease (AD), can be difficult to assess promptly because evaluation often depends on in-person specialist visits.
- Trial name
- MonitorCog-AI (NCT07883746)
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Alzheimer's Disease (AD)
Effects of Auditory Brain Stimulation by "Pink Noise" on Memory Capacities in Alzheimer's Disease: Proof of Concept Study
Alzheimer's disease (AD) is a neurodegenerative disorder affecting almost 6% of the world's population over the age of 65. This disease, in its most typical sporadic form, is characterized by an episodic memory impairment linked…
- Trial name
- PINK-AD (NCT04570761)
- Testing
- Dreem headband
- Where
- France
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Alzheimer Disease, Aging
Vanderbilt Memory and Aging Project
This study will use an observational cohort to cross-sectionally and longitudinally relate vascular health to clinical, imaging, and biological markers of early Alzheimer's disease and cerebrovascular disease among aging adults.
- Conditions
- Alzheimer Disease, Aging, Aged, 80 and Over, Biomarkers
- Trial name
- VMAP (NCT05372159)
- Testing
- none, observational study
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Vanderbilt University Medical Center
Alzheimer Disease
Study of Genetic Alzheimer's Disease Mutation Carriers in Preclinical Stages of the Disease 18F-Florbetaben Positron Emission Tomography Study
The main purpose of the study is to assess safety of a single dose of FBB followed by PET scan in individuals at risk of genetic Alzheimer's disease.
- Trial name
- NCT02362880
- Testing
- Florbetaben
- Where
- Spain
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Judit Pich Martínez
Alzheimer's Disease
Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine
The purpose of this study is to evaluate and compare the changes of cognitive function (as measured by ADAS-Cog) in the two group of patients with Alzheimer's disease (AD) associated with and without white matter changes after…
- Trial name
- CAREER (NCT01380288)
- Testing
- rivastigmine patch
- Where
- 16 sites in South Korea
- Volunteers
- 300 people
- Sponsor
- Dong-A University
Alzheimer's Disease, Mild Cognitive Impairment
A Composite MR Neuroimaging Marker for Alzheimer's Disease
The purpose of this study is to use a functional MRI (fMRI) index to compare the brain activity of healthy volunteers to that of people with mild cognitive impairment (MCI) and Alzheimer's disease.
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Frontotemporal Dementia
- Trial name
- NCT01615666
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Medical College of Wisconsin
Parkinson Disease, Alzheimer Disease
Autoimmune Features of Neurodegenerative Disorders
This study is being conducted to better understand the role of inflammation in Parkinson's disease (PD) and Alzheimer's disease (AD).
- Conditions
- Parkinson Disease, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- NCT04239079
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Columbia University
Alzheimer Disease, Progressive Supranuclear Palsy
Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls
This is an experimental medicine study to evaluate the kinetics of cerebrospinal fluid (CSF) biomarkers in subjects with Alzheimer's disease (AD) or progressive supranuclear palsy (PSP) compared to healthy controls using a heavy…
- Trial name
- NCT01348061
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- KineMed
Alzheimer Disease, Dementia
A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease
The purpose of this study is to evaluate the safety and effectiveness of galantamine (a drug for treating dementia) versus placebo in the treatment of patients with Alzheimer's disease using a flexible dose design.
- Trial name
- NCT00253227
- Testing
- galantamine hydrobromide
- Volunteers
- 387 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Subjective Cognitive Decline (SCD), Subjective Cognitive Complaints (SCCs)
The Signature of Alzheimer's Disease in Subjective Cognitive Decline
This study focuses on improving early detection of Alzheimer's disease (AD) in patients with subjective cognitive decline (SCD), a preclinical stage of cognitive impairment, in the context of emerging disease-modifying therapies…
- Conditions
- Subjective Cognitive Decline (SCD), Subjective Cognitive Complaints (SCCs), Subjective Cognitive Impairment, Subjective Cognitive Concerns
- Trial name
- SIGN-AL (NCT07402161)
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- IRCCS Policlinico S. Donato
Obstructive Sleep Apnea of Adult, Mild Cognitive Impairment
The Relationship Between Obstructive Sleep Apnea and Alzheimer's Disease: Evidence and Effectiveness
The research plan to enroll 15 simple snoring patients (apnea/hypopnea <5, control group), 30 severe OSA patients (apnea/hypopnea >30, treatment group), and 15 mild cognitive impairment patients (comparative group).
- Trial name
- OSA (NCT05433883)
- Testing
- sleep surgery
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Mild Cognitive Impairment, Mild Alzheimer's Disease
A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.
A randomized-control, double-blind, multi-center, delayed-start, pilot trial evaluating the disease modifying effects of a 150mg once-a-day dose vs.
- Trial name
- NCT03752294
- Testing
- Dabigatran
- Sponsor
- University of Rhode Island
Alzheimer Disease
The Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Mild to Moderate Alzheimer's Disease
Alzheimer's disease (AD) is the leading cause of dementia, affecting millions worldwide. With its global prevalence steadily increasing, particularly in low- and middle-income countries, the demand for effective treatments has…
- Trial name
- NCT06840054
- Testing
- Sodium Pentaborate Pentahydrate
- Volunteers
- 30 people
- Sponsor
- Tabriz University of Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.